The Food and Drug Administration’s decision to take three extra months to review Biogen’s controversial Alzheimer’s drug has brought more questions than answers, further complicating the future of what would be the first new treatment for the disease in nearly 20 years.
For Biogen, the delay could be a positive omen — or a prelude to rejection.
